Lederhandler Margo H, Ho Anthony, Brinster Nooshin, Ho Roger S, Liebman Tracey N, Lo Sicco Kristen
J Drugs Dermatol. 2018 Jul 1;17(7):807-809.
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysgeusia, and lichenoid reactions. Oral mucositis occurs more rarely in the setting of PD-1 inhibition, and few other reports of a Grade 3 or higher, severe, stomatitis have been reported in the literature. We present a case of a 78-year-old woman with Grade 3 ulcerative oral mucositis that occurred 13 months after initiation of PD-1 inhibitor, pembrolizumab, for the treatment for lung adenocarcinoma. She was successfully treated with prednisone, and pembrolizumab was temporarily held by her oncologist. Physicians should be aware of the possibility of severe mucositis in the setting of PD-1 inhibitors, as well as the management. J Drugs Dermatol. 2018;17(7):807-809.
使用抗程序性细胞死亡蛋白1（PD-1）免疫检查点抑制剂治疗恶性肿瘤可导致因T细胞激活引起的皮肤黏膜副作用。由于这些药物近期才得以研发，其全面的副作用情况仍有待充分阐明，不过皮肤不良反应最为常见。这些免疫检查点抑制剂的主要口腔毒性包括：口干、味觉障碍和苔藓样反应。在PD-1抑制的情况下，口腔黏膜炎较少发生，且文献中鲜有关于3级或更高级别的严重口腔炎的其他报道。我们报告一例78岁女性患者，在开始使用PD-1抑制剂帕博利珠单抗治疗肺腺癌13个月后发生3级溃疡性口腔黏膜炎。她接受泼尼松治疗成功，其肿瘤学家暂时停用了帕博利珠单抗。医生应意识到在使用PD-1抑制剂时发生严重黏膜炎的可能性以及应对措施。《药物皮肤病学杂志》。2018年；17（7）：807 - 809。
